Elesclomol (STA-4783)

Catalog No.S1052

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Cited by 7 Publications

Cell, 2017, 168(1-2):86-100

PubMed: 27916275 ( click the link to review the publication )

Osteoporos Int, 2018, 29(8):1917-1926

PubMed: 29860665 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):635-646

PubMed: 29917168 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 85:166-174

PubMed: 28259749 ( click the link to review the publication )

Int J Radiat Biol, 2017, 93(2):194-203

PubMed: 27600766 ( click the link to review the publication )

Oncotarget, 2016, 10.18632/oncotarget.10921

PubMed: 27486766 ( click the link to review the publication )

BMC Genomics, 2014, 15(1):263

PubMed: 24708151 ( click the link to review the publication )

4 Customer Reviews

BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.
Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Targets

HSP70 ^[1]
(Cell-free assay)

In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. ^[1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. ^[2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
NOS-1 cell	NGLSVnhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1nBdGlvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhOy54NnWtNFUh\|ryP	MU\TRW5ITVJ?
CAL-51 cell	M4rmSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MYDJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuNVI3KG6P	NIPYVoZUSU6JRWK=
ABC-1 cell	M{Wxc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3PYS2lvcGmkaYTpc44hd2ZiaIXtZY4hSUKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3PSCwTR?=	M3niXXNCVkeHUh?=
A2780 cell	MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MojZTY5pcWKrdHnvckBw\iCqdX3hckBCOjd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuOVk1KG6P	NFPZOGJUSU6JRWK=
ES1 cell	M2HqPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M4nRNmlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD63OFkhdk1?	NUTDeWdIW0GQR1XS
HUTU-80 cell	M2DGRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MVLJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc6OSCwTR?=	NIHZb5lUSU6JRWK=
NCI-H292 cell	M4XTWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NETP[XRKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OE[gcm0>	M{jGeXNCVkeHUh?=
NB69 cell	NFGwbpBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NV7mSXgxUW6qaXLpeIlwdiCxZjDoeY1idiCQQk[5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zOiCwTR?=	M4rvXnNCVkeHUh?=
ES8 cell	M3LzNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NHvRb21KdmirYnn0bY9vKG:oIHj1cYFvKEWVODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuN\|Ihdk1?	M1fuWHNCVkeHUh?=
BCPAP cell	M4\remdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NYnLO41nUW6qaXLpeIlwdiCxZjDoeY1idiCEQ2DBVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzRibl2=	NXzQb5dSW0GQR1XS
T-24 cell	M4rtPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M2rYNmlvcGmkaYTpc44hd2ZiaIXtZY4hXC1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOVUhdk1?	M4r1W3NCVkeHUh?=
EW-16 cell	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MnXjTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOlEhdk1?	NGPBU2ZUSU6JRWK=
OVCAR-5 cell	NYDCeVloT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MV7Jcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlg{KG6P	MWXTRW5ITVJ?
SF126 cell	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M2ThXmlvcGmkaYTpc44hd2ZiaIXtZY4hW0ZzMk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlk2KG6P	NYLBV5dnW0GQR1XS
KP-4 cell	NFTVVmtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MlXJTY5pcWKrdHnvckBw\iCqdX3hckBMWC12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6xO{BvVQ>?	MoGzV2FPT0WU
GAMG cell	NGDQeohIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NWLac\|E2UW6qaXLpeIlwdiCxZjDoeY1idiCJQV3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk42OSCwTR?=	M1vOVnNCVkeHUh?=
HOS cell	MnfGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Ml;WTY5pcWKrdHnvckBw\iCqdX3hckBJV1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkWzJI5O	M{PxdnNCVkeHUh?=
CHL-1 cell	NXHYb2UyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NHyyOlZKdmirYnn0bY9vKG:oIHj1cYFvKEOKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk45OSCwTR?=	M{fSO3NCVkeHUh?=
AGS cell	NGDoV5NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M4XofmlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj64OkBvVQ>?	NXTqepdDW0GQR1XS
MDA-MB-157 cell	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NVXMVZo{UW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOTV5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj65NkBvVQ>?	MVrTRW5ITVJ?
HSC-3 cell	M4jx[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NFnPZVlKdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOiCwTR?=	MXzTRW5ITVJ?
CAL-72 cell	MlnDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXLZSm9sUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytO\|Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjB{IH7N	M1rXb3NCVkeHUh?=
NBsusSR cell	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MkjRTY5pcWKrdHnvckBw\iCqdX3hckBPSnO3c2PSJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4yOyCwTR?=	MWfTRW5ITVJ?
ES7 cell	MnXKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MWPJcohq[mm2aX;uJI9nKGi3bXHuJGVUPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTNwNUmgcm0>	M1jmeHNCVkeHUh?=
H-EMC-SS cell	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MXvJcohq[mm2aX;uJI9nKGi3bXHuJGguTU2FLWPTJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{43QCCwTR?=	MX\TRW5ITVJ?
NCI-H1703 cell	NIK1dHZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1jVOmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO\|A{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy54ODDuUS=>	NFXGbGpUSU6JRWK=
BHT-101 cell	MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFLQZmVKdmirYnn0bY9vKG:oIHj1cYFvKEKKVD2xNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njd{IH7N	Ml7iV2FPT0WU
SK-OV-3 cell	NYLacY5IT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NX3qUY1{UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55NTDuUS=>	NIfWbZRUSU6JRWK=
EW-24 cell	NV;CV5FRT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVjjXnZkUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2yOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDNibl2=	M3;QZ3NCVkeHUh?=
PSN1 cell	NU[0PVA5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M2\UUGlvcGmkaYTpc44hd2ZiaIXtZY4hWFOQMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuPFQhdk1?	MXzTRW5ITVJ?
OVCAR-8 cell	M13JZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NWfmZos{UW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk05KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy57OTDuUS=>	NYHESWNuW0GQR1XS
NCI-H1563 cell	NWnIemVMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NYDXOZdzUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE2PjNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkGzJI5O	NWH4V4VVW0GQR1XS
SW756 cell	NHTKd4hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MVXJcohq[mm2aX;uJI9nKGi3bXHuJHNYPzV4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6xN{BvVQ>?	NWHCO\|UzW0GQR1XS
A375 cell	NX;E[HNyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NI\OWHFKdmirYnn0bY9vKG:oIHj1cYFvKEF\|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlE1KG6P	NUD4W\|BQW0GQR1XS
Ca9-22 cell	M3Pm[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3\WbWlvcGmkaYTpc44hd2ZiaIXtZY4hS2F7LUKyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4zPSCwTR?=	MmDZV2FPT0WU
SW1990 cell	NY\1cXhsT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MX7Jcohq[mm2aX;uJI9nKGi3bXHuJHNYOTl7MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuN\|Ihdk1?	NEPLSYFUSU6JRWK=
ES4 cell	M{n5SGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGVUPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTRwM{mgcm0>	M3y2NnNCVkeHUh?=
HCE-T cell	M3jI[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MUDJcohq[mm2aX;uJI9nKGi3bXHuJGhETS2WIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND60OUBvVQ>?	NGSweW9USU6JRWK=
MOLT-16 cell	NVP2d3RNT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MmXWTY5pcWKrdHnvckBw\iCqdX3hckBOV0yWLUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE42OyCwTR?=	M2D1UnNCVkeHUh?=
HSC-4 cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NUfXcJRTUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQCCwTR?=	NG\6fo5USU6JRWK=
NCI-SNU-1 cell	M2Tne2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NX65T2xiUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtV25WNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lki2JI5O	MUTTRW5ITVJ?
EW-11 cell	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NWrtRnMzUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQSCwTR?=	M{CycXNCVkeHUh?=
HT-1080 cell	M2PIcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M37hPGlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTlibl2=	NVz0V\|I6W0GQR1XS
MES-SA/Dx5 cells	M1;pXWN6fG:2b4jpZ4l1gSCjc4PhfS=>	NHrzZ5pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTVNvU1GvSJg2KGOnbHzzMEBKSzVyPUWgcm0>	MljSNlM6Ozd7OEG=
SW1710 cell	M4Xacmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NUHHd\|BUUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjF4IH7N	MWrTRW5ITVJ?
EW-1 cell	NFf3SZNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGVYNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkK0JI5O	MXfTRW5ITVJ?
BV-173 cell	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFjT[o9KdmirYnn0bY9vKG:oIHj1cYFvKEKYLUG3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzlibl2=	M1qwbnNCVkeHUh?=
TE-8 cell	NWLJe\|ByT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NEjJNnJKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQyKG6P	MnzMV2FPT0WU
G-401 cell	M{DYdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NUPkb3I5UW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDNibl2=	NVHRb5VFW0GQR1XS
KOSC-2 cell	NEXmWWNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NXq2bWh6UW6qaXLpeIlwdiCxZjDoeY1idiCNT2PDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjR3IH7N	Mm\nV2FPT0WU
HuCCT1 cell	M3TUe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MlLKTY5pcWKrdHnvckBw\iCqdX3hckBJfUOFVEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlUzKG6P	NHzt[WZUSU6JRWK=
FADU cell	NFLuN\|hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NEPW[ZFKdmirYnn0bY9vKG:oIHj1cYFvKE[DRGWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlY3KG6P	MkLaV2FPT0WU
MHH-ES-1 cell	Mmq1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MnrCTY5pcWKrdHnvckBw\iCqdX3hckBOUEhvRWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPjlibl2=	M1rt[3NCVkeHUh?=
ES3 cell	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NHj3[41KdmirYnn0bY9vKG:oIHj1cYFvKEWVMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuO\|khdk1?	NUfHSmhDW0GQR1XS
OVCAR-4 cell	M{\4VWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MYfJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlg4KG6P	M{LQRnNCVkeHUh?=
HD-MY-Z cell	M{TuPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M{iyWGlvcGmkaYTpc44hd2ZiaIXtZY4hUERvTWmtXkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTFibl2=	NInmPJhUSU6JRWK=
human JAR cell	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M4jBSmlvcGmkaYTpc44hd2ZiaIXtZY4hUkGUIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT65O{BvVQ>?	NEPXcWtUSU6JRWK=
A427 cell	NYfzT\|hlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MYLJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkC3JI5O	MXnTRW5ITVJ?
697 cell	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmHhTY5pcWKrdHnvckBw\iCqdX3hckA3QTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkGzJI5O	NEjtXZpUSU6JRWK=
OVCAR-3 cell	MmCzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MULJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlIhdk1?	NUO0UHlQW0GQR1XS
human NB14 cell	M1;zb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NFL6TYhKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY1KG6P	MXrTRW5ITVJ?
GB-1 cell	NGjsS3VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NWOw[XN7UW6qaXLpeIlwdiCxZjDoeY1idiCJQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44OSCwTR?=	M3\iR3NCVkeHUh?=
COR-L105 cell	NYfTPI03T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Ml;oTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEGwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPzZibl2=	NX3z[ZFPW0GQR1XS
647-V cell	NWHFc\|NMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MWHJcohq[mm2aX;uJI9nKGi3bXHuJFY1Py2YIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nj65JI5O	MoXZV2FPT0WU
human K5 cell	M1\mXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NXHkfIREUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUegcm0>	Mo\iV2FPT0WU
DMS-273 cell	NYXHPHM6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NUnSSYFZUW6qaXLpeIlwdiCxZjDoeY1idiCGTWOtNlc{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yNjDuUS=>	MWXTRW5ITVJ?
UM-UC-3 cell	MlnGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NUm5ZYFkUW6qaXLpeIlwdiCxZjDoeY1idiCXTT3VR{0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yNjDuUS=>	NIHmN\|ZUSU6JRWK=
HEL cell	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MWHJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTdwMEigcm0>	M1vPPXNCVkeHUh?=
human KU-19-19 cell	M2HibWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NWjqT5Q5UW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTdwMEmgcm0>	NGOw[VFUSU6JRWK=
MC-IXC cell	MmW5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXPDU3JDUW6qaXLpeIlwdiCxZjDoeY1idiCPQz3JXGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjF5IH7N	MnO1V2FPT0WU
human H4 cell	Mk\ZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NIi1dFlKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nz6yOUBvVQ>?	MlvQV2FPT0WU
NUGC-3 cell	NWflOpVxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MW\Jcohq[mm2aX;uJI9nKGi3bXHuJG5WT0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUeuN\|Mhdk1?	NIr2bJFUSU6JRWK=
CHP-212 cell	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NVX0cIJXUW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5\|NDDuUS=>	M1TJO3NCVkeHUh?=
human SW982 cell	M1TjZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3vFNmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlQ1KG6P	NIS1OZJUSU6JRWK=
C-33-A cell	NX;Ob3Z4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mof0TY5pcWKrdHnvckBw\iCqdX3hckBENTN\|LVGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlU5KG6P	Mm\uV2FPT0WU
PC-3 cell	NH3qWlFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NWTDRnF{UW6qaXLpeIlwdiCxZjDoeY1idiCSQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45QSCwTR?=	NWrTT3BlW0GQR1XS
COLO-684 cell	MmjkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MlvpTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvOjFibl2=	M{jTN3NCVkeHUh?=
SNU-387 cell	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NHSzRodKdmirYnn0bY9vKG:oIHj1cYFvKFOQVT2zPFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06NjR7IH7N	NV3hUJhUW0GQR1XS
U251 cell	M4H2S2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MnuyTY5pcWKrdHnvckBw\iCqdX3hckBWOjVzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;OT64OkBvVQ>?	NVPzWW5QW0GQR1XS
A673 cell	MoW4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MmfKTY5pcWKrdHnvckBw\iCqdX3hckBCPjd\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MUGuOkBvVQ>?	NHH4cYhUSU6JRWK=
human T47D cell	NIq0emVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MWTJcohq[mm2aX;uJI9nKGi3bXHuJHQ1P0RiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNj63PUBvVQ>?	NFjlVFBUSU6JRWK=
A549 cell	NXPN[Wh2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MYjJcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zOT62JI5O	NWX0PIFTW0GQR1XS
PC-14 cell	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Mke4TY5pcWKrdHnvckBw\iCqdX3hckBRSy1zNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUK0Mlc{KG6P	NGLPc5lUSU6JRWK=
A704 cell	M4XrcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NXTMRnNyUW6qaXLpeIlwdiCxZjDoeY1idiCDN{C0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlcvPDVibl2=	MVLTRW5ITVJ?
MCF7 cell	NEHjPVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MVHJcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|MT6zOkBvVQ>?	NI\IS2NUSU6JRWK=
PC3 cells	NFuzV\|JHfW6ldHnvckBie3OjeR?=	M2LSOWlvcGmkaYTpc44hd2ZiUFTLNU1u\WSrYYTl[EBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IGTodlMxQCC{ZYPp[JVmKGmwIHj1cYFvKFCFMzDj[YxteyCkeTDFUGlUSSxiSVO1NF0xNjFzMzFOwG0>	MX[yNVM1OTZ5NR?=
F-36P cells	Mk\UVJJwdGmoZYLheIlwdiCjc4PhfS=>	NWPwNZcySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDGMVM3WCClZXzsd{whUUN3ME2wMlI5KM7:TR?=	M4Hie\|IyOzRzNke1
OCI-AML2 cells	MXfQdo9tcW[ncnH0bY9vKGG\|c3H5	NUDsW\|JJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDPR2kuSU2OMjDj[YxteyxiSVO1NF0xNjN3IN88US=>	NIq2XGozOTN2MU[3OS=>
K562 cells	NXzpVo5LWHKxbHnm[ZJifGmxbjDhd5NigQ>?	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNuIFnDOVA:OThizszN	NX;KUlZqOjF\|NEG2O\|U>

... Click to View More Cell Line Experimental Data

In vivo

Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. ^[4]

Protocol

Cell Research:^[1]	- Collapse Cell lines: Hs294T, HSB2, and Ramos Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM Incubation Time: 18, or 24 hours Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit. (Only for Reference)
Animal Research:^[4]	- Collapse Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors Formulation: Dissolved in DMSO, and diluted in saline Dosages: ~100 mg/kg Administration: Intravenous injection (Only for Reference)

Cell Research:^[1]

- Collapse

Cell lines: Hs294T, HSB2, and Ramos
Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
Incubation Time: 18, or 24 hours
Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
(Only for Reference)

Animal Research:^[4]

- Collapse

Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
Formulation: Dissolved in DMSO, and diluted in saline
Dosages: ~100 mg/kg
Administration: Intravenous injection
(Only for Reference)

References

[4] Gehrmann M. Curr Opin Investig Drugs, 2006, 7(6), 574-580.

- Collapse

Solubility (25°C)

In vitro	DMSO	80 mg/mL (199.75 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% DMSO+30% polyethylene glycol+1% Tween 80 For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Elesclomol (STA-4783) SDF

Molecular Weight	400.5
Formula	C₁₉H₂₀N₄O₂S₂
CAS No.	488832-69-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How can we use the compound for in vivo mouse studies?
Answer:
S1052 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension, it is fine for oral administration. You can also dissolve S1052 in 0.5-1% CMC-Na solution and treat the mice by oral gavage.

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Tanespimycin (17-AAG)

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Features:Displays very low toxicity toward normal cells.
Luminespib (AUY-922, NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Elesclomol (STA-4783)

Cited by 7 Publications

4 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Elesclomol (STA-4783) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

Choose Your Country or Region

By Signaling Pathways

By product type

Elesclomol (STA-4783)

Cited by 7 Publications

4 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Elesclomol (STA-4783) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)